Department of Pharmacy, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Department of Infection, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Biosci Trends. 2020 Jul 17;14(3):161-167. doi: 10.5582/bst.2020.03106. Epub 2020 Jun 12.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become a serious public health threat to the whole world, and the number of infected is still rising dramatically at this moment. Several studies have confirmed that cytokine storms play a critical role in causing a case to worsen from mild to severe or critical. The current treatment for cytokine storms is limited, so the international medical community is focusing on a specific and effective remedy. Jaktinib hydrochloride is a broad spectrum JAK inhibitor. It can inhibit cytokine-induced immune activation by multiple mechanisms and also slow viral proliferation by inhibiting AAK1 without causing unacceptable toxicity. Jaktinib hydrochloride has great potential for the treatment of patients with coronavirus disease 2019 (COVID-19).
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染已成为全世界严重的公共卫生威胁，目前感染人数仍在急剧上升。有几项研究证实，细胞因子风暴在导致病情从轻度恶化到重度或危重度方面起着关键作用。目前治疗细胞因子风暴的方法有限，因此国际医学界正在关注一种特定而有效的治疗方法。盐酸杰克替尼是一种广谱 JAK 抑制剂。它可以通过多种机制抑制细胞因子诱导的免疫激活，也可以通过抑制 AAK1 来减缓病毒增殖，而不会引起不可接受的毒性。盐酸杰克替尼对治疗 2019 冠状病毒病（COVID-19）患者具有巨大的潜力。
